Reviva soars on success of schizophrenia drug in late-stage trial

Reviva Pharmaceuticals Holdings

30/10/2023 12:03

** Shares of drug developer Reviva Pharmaceuticals  RVPH.O 
rise 19.2% to $4.47 premarket
    ** Company says its experimental drug, brilaroxazine, to
treat adults with schizophrenia met the main goal of a
late-stage study
    ** RVPH expects to file a marketing application to U.S. FDA
in 2025 
    ** Schizophrenia is a chronic mental disorder that causes
distortion in thoughts, hallucinations and feelings of fright
and paranoia
    ** Up to last close, shares down 11.8% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))